Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RMD 
ResMed Inc (RMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: RMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $294.73
1 Year Target Price $294.73
| 8 | Strong Buy |
| 4 | Buy |
| 6 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.93% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 39.13B USD | Price to earnings Ratio 28.16 | 1Y Target Price 294.73 |
Price to earnings Ratio 28.16 | 1Y Target Price 294.73 | ||
Volume (30-day avg) 19 | Beta 0.83 | 52 Weeks Range 199.07 - 293.81 | Updated Date 10/19/2025 |
52 Weeks Range 199.07 - 293.81 | Updated Date 10/19/2025 | ||
Dividends yield (FY) 0.79% | Basic EPS (TTM) 9.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-23 | When After Market | Estimate 2.51 | Actual - |
Profitability
Profit Margin 27.22% | Operating Margin (TTM) 33.87% |
Management Effectiveness
Return on Assets (TTM) 14.02% | Return on Equity (TTM) 25.86% |
Valuation
Trailing PE 28.16 | Forward PE 25.91 | Enterprise Value 40015405993 | Price to Sales(TTM) 7.6 |
Enterprise Value 40015405993 | Price to Sales(TTM) 7.6 | ||
Enterprise Value to Revenue 7.78 | Enterprise Value to EBITDA 20.81 | Shares Outstanding 145940728 | Shares Floating 145477784 |
Shares Outstanding 145940728 | Shares Floating 145477784 | ||
Percent Insiders 0.62 | Percent Institutions 65.12 |
Upturn AI SWOT
ResMed Inc
Company Overview
History and Background
ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. It evolved from Baxter Healthcare, focusing initially on devices for sleep apnea. ResMed has grown through product innovation and strategic acquisitions, expanding its presence in sleep apnea, COPD, and other respiratory conditions.
Core Business Areas
- Sleep and Respiratory Care Devices: This segment designs, manufactures, and distributes a range of CPAP and bilevel devices, masks, and accessories for the treatment of sleep apnea and other respiratory disorders.
- Software as a Service (SaaS): This segment provides cloud-based software solutions for managing patient data and optimizing healthcare workflows, primarily focused on home healthcare and skilled nursing facilities.
Leadership and Structure
ResMed is led by CEO Michael Farrell. The organizational structure includes distinct business units focused on sleep and respiratory care, as well as software solutions. Senior leadership also includes a Chief Financial Officer, Chief Technology Officer, and various regional presidents.
Top Products and Market Share
Key Offerings
- AirSense 11: A CPAP (Continuous Positive Airway Pressure) machine designed for treating sleep apnea. It features personalized therapy options and remote monitoring capabilities. Competitors include Philips Respironics (PHG) and Fisher & Paykel Healthcare (FPH).
- AirFit F20 Mask Series: A full-face mask used with CPAP devices for sleep apnea therapy. Provides comfort and seal. Competitors include Philips DreamWear Full Face Mask and Fisher & Paykel Simplus Mask.
- Brightree: A cloud-based software platform for home medical equipment (HME) providers and pharmacies. Competitors include WellSky and CareTend.
Market Dynamics
Industry Overview
The respiratory care and sleep apnea market is experiencing growth driven by aging populations, increasing awareness of sleep disorders, and technological advancements in treatment options. Telehealth and remote patient monitoring are also growing trends.
Positioning
ResMed holds a leading position in the sleep apnea device market and is expanding its presence in the respiratory care and software solutions space. Its competitive advantages include a strong brand reputation, innovative product portfolio, and a global distribution network.
Total Addressable Market (TAM)
The global sleep apnea devices market is estimated to reach approximately $13 billion by 2030. ResMed is well-positioned to capitalize on this market with its comprehensive product offerings.
Upturn SWOT Analysis
Strengths
- Strong Brand Recognition
- Extensive Product Portfolio
- Global Distribution Network
- Innovation in Respiratory Care Technology
- Recurring Revenue from SaaS solutions
Weaknesses
- Dependence on reimbursement policies
- Exposure to regulatory changes
- Competition from established players
- Potential supply chain vulnerabilities
Opportunities
- Expansion into emerging markets
- Growth in telehealth and remote monitoring
- Development of new therapies for respiratory diseases
- Strategic acquisitions to expand product offerings
- Increased focus on patient adherence and compliance
Threats
- Price competition from generic manufacturers
- Product recalls or safety concerns
- Changes in healthcare regulations
- Economic downturns affecting patient spending
- Technological disruptions from new entrants
Competitors and Market Share
Key Competitors
- PHG
- FPH
Competitive Landscape
ResMedu2019s advantages include a strong brand reputation and innovative product portfolio. Philips (PHG) is a major competitor in the device market, while Fisher & Paykel (FPH) is also a significant player. ResMed's SaaS solutions provide a competitive edge in the healthcare software space.
Major Acquisitions
Propeller Health
- Year: 2019
- Acquisition Price (USD millions): 225
- Strategic Rationale: Expanded ResMed's digital health offerings and strengthened its position in connected respiratory care.
MatrixCare
- Year: 2018
- Acquisition Price (USD millions): 750
- Strategic Rationale: Strengthened ResMed's position in the out-of-hospital care software market.
Growth Trajectory and Initiatives
Historical Growth: ResMed has experienced consistent revenue growth over the past decade, driven by increasing demand for its sleep apnea devices and software solutions.
Future Projections: Analysts project continued revenue growth for ResMed, driven by increasing awareness of sleep disorders and the expansion of its product portfolio.
Recent Initiatives: Recent initiatives include investments in telehealth and remote patient monitoring, strategic acquisitions to expand product offerings, and partnerships to develop new therapies for respiratory diseases.
Summary
ResMed is a strong company with a leading position in the sleep apnea device market. Its focus on innovation, strategic acquisitions, and SaaS solutions has driven consistent revenue and earnings growth. However, ResMed needs to be mindful of competitive pressures and regulatory changes in the healthcare industry and should pursue expansion into emerging markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ResMed Inc
Exchange NYSE | Headquaters San Diego, CA, United States | ||
IPO Launch date 1995-06-02 | CEO & Chairman Mr. Michael J. Farrell BE, MBA, SM | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 10600 | Website https://www.resmed.co.in |
Full time employees 10600 | Website https://www.resmed.co.in | ||
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.